A quarterly analytical discussion on study startup
The ChromoReport is a quarterly analytical discussion on study startup utilizing anonymized aggregated clinical data from leading Pharmas and CROs, representing over 70 percent of clinical trial sites engaged in phase II & III studies.
Recent research from the KMR Group on global site contract cycle times highlights why tracking the sub-steps in contract execution is critical. Their study, evaluating 20,000 recently-executed contracts for Phase II and III trials from leading biopharmaceutical companies, found that overall contract cycle times have doubled from an industry median of 1.5 months in 2009-2011 to more than 3 months in 2014-2015. Even contracts conducted in North America, traditionally a top performer, increased from 1.3 months in 2010-2011 to 2.4 in 2014-2015. Cycle times in emerging markets were even longer.
Additionally, in a survey of more than 400 investigative sites, CenterWatch found that contract and budget negotiations with investigative sites are protracted and fraught with delays, contributing to slow study startup timelines.
What do the industry metrics have to say about contract timelines in study startup?
Download the June 2018 edition of the ChromoReport today! Fill out the form to get your copy.